Emmaus Life Sciences, Inc. (EMMA)
OTCMKTS · Delayed Price · Currency is USD
0.0086
-0.0054 (-38.57%)
Jan 17, 2025, 4:00 PM EST

Emmaus Life Sciences Company Description

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.

The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Its pipeline products include ELS001/ELS007, a pharmaceutical grade L-glutamine, which has completed phase 3 clinical trial to treat sickle cell disease; ELS004, a pharmaceutical grade L-glutamine which has completed phase 1 clinical study to treat diverticulosis; ELS005 in preclinical study for the use and combination of KM10544 to treat blood cancers; ELS003, a lab device/research tool in preclinical study to measure transmittance of cell sheet; and ELS002, a chondrocyte cell sheet technology to replace knee cartilage replacement or to treat osteoarthritis is in preclinical study.

It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor (KM10544) for the treatment of cancers.

The company was founded in 2000 and is headquartered in Torrance, California.

Emmaus Life Sciences, Inc.
Emmaus Life Sciences logo
Country United States
Founded 2000
Industry Biotechnology
Sector Healthcare
Employees 55
CEO Willis Lee

Contact Details

Address:
21250 Hawthorne Boulevard
Torrance, Delaware 90503
United States
Phone 310 214 0065
Website emmausmedical.com

Stock Details

Ticker Symbol EMMA
Exchange OTCMKTS
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
ISIN Number US29137T1016
SIC Code 2834

Key Executives

Name Position
Willis C. Lee M.S. Chief Executive Officer and Chairman of the Board
Yasushi Nagasaki CPA, CPA Chief Financial Officer
Dr. Charles W. Stark Pharm.D, Pharm.D. Chief Science Officer and Executive Vice President of Clinical Development, Medical Affairs, Clinical and Regulatory
Dale E. Short J.D. Legal Consultant and Corporate Secretary
Kurt H. Kruger M.B.A., M.S. Consultant